RayzeBio, Inc. (RYZB)
Total Valuation
RayzeBio has a market cap or net worth of $1.34 billion. The enterprise value is $809.62 million.
| Market Cap | 1.34B |
| Enterprise Value | 809.62M |
Important Dates
The last earnings date was Monday, November 13, 2023, after market close.
| Earnings Date | Nov 13, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
RayzeBio has 59.92 million shares outstanding. The number of shares has increased by 472.44% in one year.
| Shares Outstanding | 59.92M |
| Shares Change (YoY) | +472.44% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.33 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 31.85, with a Debt / Equity ratio of 0.02.
| Current Ratio | 31.85 |
| Quick Ratio | n/a |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$753,909 |
| Employee Count | 88 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (1Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 20.73 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 57.28 |
| Average Volume (30 Days) | 301,617 |
Short Selling Information
The latest short interest is 1.70 million, so 2.84% of the outstanding shares have been sold short.
| Short Interest | 1.70M |
| Short Previous Month | 1.73M |
| Short % of Shares Out | 2.84% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | n/a |
| Pretax Income | n/a |
| Net Income | -66.34M |
| EBITDA | n/a |
| EBIT | n/a |
| Earnings Per Share (EPS) | -$1.21 |
Balance Sheet
The company has $540.51 million in cash and $9.72 million in debt, giving a net cash position of $530.78 million or $8.86 per share.
| Cash & Cash Equivalents | 540.51M |
| Total Debt | 9.72M |
| Net Cash | 530.78M |
| Net Cash Per Share | $8.86 |
| Equity / Book Value | 575.32M |
| Book Value Per Share | 9.60 |
| Working Capital | 527.87M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RayzeBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -4.95% |
| FCF Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -472.44% |
| Shareholder Yield | -472.44% |
Analyst Forecast
The average price target for RayzeBio is $31.33, which is 40.05% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $31.33 |
| Price Target Difference | 40.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |